Table 2.
Patient characteristics at baseline (FAS)
| |
Placebo |
Tofogliflozin |
|||
|---|---|---|---|---|---|
| 10 mg | 20 mg | 40 mg | |||
| n |
56 |
57 |
58 |
58 |
|
| Age (years), Mean (SD) |
56.8 (9.9) |
58.6 (9.8) |
56.6 (10.2) |
57.0 (9.1) |
|
| Gender, n (%) |
Male |
37 (66.1%) |
38 (66.7%) |
39 (67.2%) |
39 (67.2%) |
| Female |
19 (33.9%) |
19 (33.3%) |
19 (32.8%) |
19 (32.8%) |
|
| Body weight (kg), Mean (SD) |
71.20 (12.64) |
67.26 (12.67) |
68.06 (15.82) |
68.72 (11.91) |
|
| BMI (kg/m2), Mean (SD) |
26.00 (4.11) |
25.07 (3.53) |
24.99 (4.55) |
25.78 (4.10) |
|
| HbA1c (%), Mean (SD) |
8.41 (0.78) |
8.45 (0.75) |
8.34 (0.81) |
8.37 (0.77) |
|
| Fasting plasma glucose (mg/dL), Mean (SD) |
168.8 (24.9) |
170.2 (32.4) |
168.7 (29.6) |
167.9 (37.0) |
|
| eGFR (mL/min/1.73 m2), Mean (SD) |
83.78 (17.68) |
84.90 (20.15) |
86.78 (19.62) |
86.00 (18.18) |
|
| Systolic blood pressure (mmHg), Mean (SD) |
128.3 (13.7) |
128.0 (15.6) |
131.3 (12.9) |
129.3 (12.5) |
|
| Diastolic blood pressure (mmHg), Mean (SD) |
76.7 (11.4) |
78.6 (10.6) |
79.2 (11.7) |
78.7 (9.0) |
|
| Duration of diabetes (years), Mean (SD) |
6.0 (6.1) |
6.3 (7.1) |
6.4 (5.1) |
6.7 (5.5) |
|
| Prior treatment of diabetes |
Yes |
16 (28.6%) |
15 (26.3%) |
23 (39.7%) |
16 (27.6%) |
| No | 40 (71.4%) | 42 (73.7%) | 35 (60.3%) | 42 (72.4%) | |
Abbreviations: BMI body mass index, eGFR estimated glomerular filtration rate.